Aflibercept and Bevacizumab for Diabetic Maculopathies

NCT06850571 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Maculopathy

Interventions

DRUG: Bevacizumab Injection [Avastin]
DRUG: Aflibercept 2Mg/0.05Ml Inj,Oph

Sponsor

Al-Mustansiriyah University

Collaborators

[object Object]